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RESUMO
Introdução: A intoxicação por monóxido de carbono pode ocorrer em diversos contextos. 
Material e Métodos: Retrospectiva de 37 casos de intoxicação por monóxido de carbono submetidos a oxigenoterapia hiperbárica 
nos fogos do Funchal de agosto de 2016. 
Resultados: Foram analisados 37 doentes, com média de 38 anos e 78% do sexo masculino; o universo de casos analisados incluiu 
10 bombeiros, quatro crianças e duas grávidas; 80% reportaram sintomas neurológicos. O nível mediano de carboxihemoglobina foi 
de 3,7%. Todos receberam oxigénio alto débito até iniciarem oxigenoterapia hiperbárica. A persistência de sintomas foi a principal 
indicação para oxigenoterapia hiperbárica. O tempo mediano para oxigenoterapia hiperbárica foi 4,8 horas, a 2,5 ATA durante 90 
minutos, sem intercorrências relevantes. O tempo até alta foi inferior a 24 horas em 92% dos casos. Follow-up 30 dias: cinco doentes 
apresentavam sinais clínicos de síndrome neurológico tardio; doze foram perdidos no follow-up. Os níveis de carboxihemoglobina 
durante a admissão e tempo médio até oxigenoterapia hiperbárica não diferiram entre os doentes que desenvolveram a síndrome a 
30 dias e os restantes (p = 0,44 e p = 0,58, respetivamente). 
Discussão: A ocorrência de síndrome neurológico tardio a 30 dias ocorreu em 20% dos doentes, não se tendo verificado novos casos 
ao fim de 12 meses. 
Conclusão: A oxigenoterapia hiperbárica parece ter permitido reduzir a incidência de síndrome neurológico tardio. Esta é a primeira 
série de casos portuguesa que reporta exclusivamente a utilização de oxigenoterapia hiperbárica na intoxicação por monóxido de 
carbono por fogos florestais. Os autores pretendem alertar para importância destes doentes, cuja indicação terapêutica e benefício 
clínico deste tratamento está bem documentada, sobretudo atendendo à crescente problemática dos incêndios florestais em Portugal.
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ABSTRACT
Introduction: Carbon monoxide poisoning may occur in several contexts. 
Material and Methods: Retrospective of 37 carbon monoxide poisoning cases that underwent hyperbaric oxygen during wildfires in 
Funchal in August 2016. 
Results: The studied sample included 37 patients, mean age of 38 years, 78% males. Ten were firefighters, four children and two 
pregnant victims. Neurological symptoms were the most reported. Median carboxyhemoglobin level was 3.7% (IQR 2.7). All received 
high-flow oxygen from admission to delivery of hyperbaric oxygen. Persistence of symptoms was the main indication for hyperbaric 
oxygen. Median time to hyperbaric oxygen was 4.8 hours (IQR 9.5), at 2.5 ATA for 90 minutes, without major complications. Discharge 
in less than 24 hours occurred in 92% of the cases. Thirty days follow-up: five patients presented clinical symptoms of late neurological 
syndrome; twelve patients were lost to follow-up. Carboxyhemoglobin levels on admission and mean time to hyperbaric oxygen were 
no different between those who did and did not develop the syndrome at 30 days (p = 0.44 and p = 0.58, respectively). 
Discussion: Late neurological syndrome at 30 days occurred in 20% and no new cases were reported at 12 months. 
Conclusion: Use of hyperbaric oxygen appears to have reduced the incidence of the syndrome. This seems to be the first Portuguese 
series reporting use of hyperbaric oxygen in carbon monoxide poisoning due to wildfires. The authors intend to alert to the importance 
of referral of these patients because the indications and benefits of this treatment are well documented. This is especially important 
given the ever-growing issue of wildfires in Portugal.
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INTRODUCTION
 Carbon monoxide (CO) poisoning can occur in several 
contexts. It can be voluntary or accidental. The leading cause 
of CO poisoning is smoke inhalation, usually in enclosed 
spaces such as houses. United States (US) estimates of 
CO poisoning point to around 50 000 cases annually, an 
incidence of 16 cases per 100 000.1 Additionally, the same 
author reported that almost 1500 CO poisoned patients are 
treated with hyperbaric oxygen therapy (HBOT) in the US 
annually.2
 A study from Braubach et al in Europe showed that 
from 1980 to 2008 there were 140 490 deaths from CO 
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mortality rate of 2.24 per 100 000 inhabitants.3 Moreover, 
a study conducted in Portugal (2000 - 2007) showed 621 
admissions due to CO poisoning. In such study, there was 
a national annual mean of 77.6 cases, roughly 2.2% of all 
admissions for intoxication and other drug effects.4
 Inhaled CO can cause toxicity through several 
mechanisms by both hypoxic stress from binding to 
haemoglobin and intracellular sites, as well as non-hypoxic 
pathways such as oxidative stress, endothelial leukocyte 
adhesion, and lipid peroxidation.5
 There is a large spectrum of clinical features due to 
CO poisoning ranging from nausea and dizziness to coma, 
with death occurring in about 1% - 3%.6 Interestingly, initial 
carboxyhemoglobin (COHb) level does not correlate with 
exhibited symptoms.6,7 
 CO poisoning is ideally diagnosed by a clinical triad: 1) 
symptoms consistent with CO poisoning, 2) history of recent 
CO exposure, and 3) elevated COHb levels.7,8 However, 
criteria are not rigid.5
 COHb levels are considered to be elevated, and may 
produce symptoms, when ≥ 2% in non-smokers and more 
than 10% in smokers.5
 Up to 40% of patients may remain with neuropsychiatric 
deficits, named the delayed neuropsychiatric syndrome 
(DNS).7 These include headache, cognitive impairment, 
lethargy, emotional liability, memory loss, dementia, 
psychosis, parkinsonism, chorea, apraxia, agnosia, 
peripheral neuropathy and urinary incontinence.5,9 
Symptoms may resolve over time but there is high proba-
bility of becoming chronic.4,8,10,11
 There is no known antidote for CO poisoning. However, 
administration of 100% normobaric oxygen therapy (NBOT) 
and HBOT may accelerate CO clearance.7 These are the 
current treatment options, with HBOT having conflicting 
results in the decrease of incidence of late neurologic 
sequelae.8 Some of the higher quality evidence comes from 
the study of Weaver et al, where HBOT showed significant 
improvement in long-term neurocognitive dysfunction.12
 According to the Tenth European Consensus Conference 
on Hyperbaric Medicine from the European Committee 
for Hyperbaric Medicine, HBOT is recommended in the 
treatment of CO poisoning as a type 1 recommendation, 
level B evidence. Furthermore, it is stated that 100% oxygen 
should be applied immediately to any CO poisoned person 
as a first aid treatment (Type 1 recommendation, Level C 
evidence). Altered consciousness, clinical neurological, 
cardiac, respiratory or psychological signs regardless 
of the COHb level at the time of hospital admission and 
CO-poisoned pregnant women regardless of their clinical 
presentation and COHb level at hospital admission are 
both type 1 recommendation, level B evidence.13 As such, 
persistence of symptoms despite NBOT is one of the main 
indications for the use of HBOT.13,14,15
 Intense wild and urban fires swept the metropolitan area 
of Funchal in Madeira Island, Portugal, starting in August 8th 
2016 under the triad of extreme heat (mean temperatures 
of 29.5º Celsius), low humidity and strong winds. This 
was an almost unprecedented set of environmental 
conditions for this subtropical Atlantic island that lasted 
five days. Wildfires progressed to urban areas leading 
to the evacuation of thousands of people, with hundreds 
coming to the emergency department (ED) for treatment. 
Moreover, three people were killed and over 300 buildings 
were damaged, leading the government to declare state 
of emergency for the city. We describe what we believe to 
be, in such a short period of time, the biggest Portuguese 
case series of patients undergoing HBOT for CO poisoning 
due to wildfires. The aims of this study were to describe 
a case series of CO poisoning in the context of wildfires 
and compare the DNS incidence at 30 days according to 
COHb concentration on arrival as well as the time to HBOT 
delivery. 
MATERIAL AND METHODS
 Retrospective, observational study of 37 patients 
that underwent hyperbaric oxygen due to CO accidental 
poisoning during the Madeira island wildfires in 2016. 
Hyperbaric oxygen session reports were reviewed from 
8 through 11th August, 2016, following intense wildfires 
that swept Funchal, Portugal. During this period an 
unprecedented case series underwent HBOT due to CO 
poisoning. 
 We collected demographic, clinical and laboratory data, 
as well as details from HBOT and early follow-up at 30 
days and one year. A 30-day appointment was scheduled 
by Hyperbaric Medicine physicians from the institution that 
also co-author this study. Clinical interview and examination 
was conducted but no structured questionnaire was 
employed. A telephone contact for DNS symptom screening 
was performed at 12 months by the authors/investigators. 
Prior authorization was obtained from the institution’s Ethics 
Committee, with favourable view. The decompression 
protocol was based on the tables and proceedings for dive 
with compressed air from the Defense and Civil Institute of 
Environmental Medicine – Canadian Military Forces. The 
paediatric group comprises the age group between 0 - 18 
years-old. Descriptive statistical analysis and comparison of 
medians with the Mann-Whitney test was performed using 
IBM SPSS Statistics for Windows v23 (Armonk, NY: IBM 
Corp.). Significance was set at a p value < 0.05.
RESULTS
 A total of 37 patients aged between 14 – 71-years-
old underwent HBOT treatment. In this series, 10 were 
firefighters, four were children and two were pregnant 
victims. The demographic distribution can be analysed 
through Fig. 1. 
 Information regarding the site of exposure was present 
for 25 patients. The majority of these (96%) experienced 
intoxication while outdoors. Two firefighters also reported 
exposure to indoor smoke. Descriptive data for the case 
series is presented in Table 1. 
 Most patients had neurological symptoms on admission 
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Figure 1 – Patient age group distribution
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Table 1 – Patient characteristics
Total number of patients 37
Number of males (%) 29 (78)
Age (years), median (IQR) 38 ± 26
Outdoor smoke exposure, n (%) 24 of 25 (96)















COHb (%), median (IQR) 3.7 ± 2.7
Time to HBOT chamber, median (IQR) 4.8 ± 9.5




Nonspecific repolarizing findings 1
Initial laboratory values, median (IQR)
pH 7.42 ± 0.14
pCO2 (mmHg) 35 ± 14.1
pO2 (mmHg) 93 ± 117.1
HCO3- (mmol/L) 23 ± 2.9
Lactate (mmol/L) 1.3 ± 1.0
CK (UI/L) 363.5 ± 389.5
CK-MB (UI/L) 21 ± 9.5
hsTroponin T 0.009 ± 0.013
Creatinine (mg/dL) 1.13 ± 0.405
Rhabdomyolysis (CK > 171 UI/L) n, (%)   20 (54)
AKI (creatinine > 1.20 mg/dL)   9 (54)
Rhabdomyolysis and AKI   8 (22)
IQR: interquartile range; COPD: chronic obstructive pulmonary disease; COHb: carboxihemoglobin; HBOT: hyperbaric oxygen therapy; CK: creatinine kinase; CK-MB: creatinine kinase 
muscle-brain fraction; AKI: acute kidney injury
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(n = 23) followed by dizziness (n = 14). Moreover, five 
patients had syncope at the wildfire scene. Dyspnoea was 
the most frequent cardiopulmonary symptom, reported 
by 23 patients. Almost 50% of patients had symptoms 
related to two or more organs and systems (n = 18). 
Electrocardiogram was normal in most patients although 
five patients exhibited sinus tachycardia. 
 Median COHb levels were not statistically different 
between smokers and non-smokers: 2.9 (IQR 4.5) and 3.7 
(IQR 2.6) with p = 0.41, respectively.
 Laboratory findings were mostly normal, except for mild 
rhabdomyolysis (median creatinine kinase (CK) 363.5 UI/L) 
and mild acute kidney injury [Acute Kidney Injury Network 
(AKIN) level 1]. Both findings were transient.
 All patients arrived at the emergency department under 
oxygen therapy and received NBOT through admission until 
the HBOT session. The persistence of symptoms despite 
NBOT was the main indication for the use of HBOT in this 
context. 
 Median time to HBOT chamber was 4.8 hours (IQR 
9.5). HBOT was performed at 15 metres (2.5 ATA) for 90 
minutes, without major complications. Treatment had to 
be withheld temporarily in two patients due to transitory 
decreased mental status. Both patients soon resumed 
treatment without further complications. One patient had a 
second session after the first one was interrupted due to 
lipothymia. 
 Time to discharge was less than 24 hours in 34 
patients (92%) although one patient required short duration 
inpatient treatment for four days due to decompensated 
chronic obstructive pulmonary disease. Table 2 shows 
the differences in COHb concentration and time to HBOT 
between patients who went on to develop DNS at 30 days 
and the remaining patients.
Delayed neuropsychiatric syndrome 
 All patients were scheduled for a 30-day follow-up 
appointment. From the 37 patients, 12 were lost to follow-
up, after missing the scheduled appointment. Of the 25 
evaluated patients, five had clinical symptoms compatible 
with DNS, meaning an estimated incidence of 20% in this 
case series. Reassessment of patients and DNS diagnosis 
at 30 days was performed based on clinical interview 
and clinical examination for all patients. No structured 
questionnaire was used.
 No new cases were registered at 12 months. One 
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Table 2 – Median (IQR) comparison of admission COHb and time to HBOT chamber in patients with and without clinical symptoms of DNS 
at 30 days
Clinical symptoms of DNS
Yes No p value
COHb (%) 4.1 (5.7) 4.2 (2.6) 0.44
Time to HBOT (hours) 9.1 (12.7) 5.9 (10.7) 0.58
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patient mentioned de novo impairment of verbal fluency that 
started around six months after the intoxication. However, 
neurological consultation excluded DNS as cause for these 
findings. Fig. 2 allows for detailed data on follow-up losses 
and incidence calculation for this series.
DISCUSSION
 Extreme environmental conditions in Funchal during 
the wildfires of August 2016 created a state of emergency 
and the need for the activation of a major response plan 
and proceedings. Due to its location, the island is equipped 
with a Hyperbaric Unit under 24-hour schedule with on-
call specialist physicians, consisting of a 7-seat hyperbaric 
chamber. This allowed for a rapid intervention, with a quick 
start of HBOT in an unusually large number of patients in a 
short period.
 This series also stands out by the number of patients 
who were intoxicated in an outdoor environment. According 
to reference Sá et al, the majority of CO intoxications in 
Portugal occur in indoors environments.4
 Most patients had clinical symptoms compatible with 
target organ damage (neurologic or cardiovascular). The 
persistence of symptoms despite NBOT was the main 
reason for upfront HBOT upon arrival and quick initial 
approach to these patients. COHb levels of at least 3% – 
4% in non-smokers and at least 10% in smokers are usually 
considered outside the expected physiological range. The 
COHb level in smokers is generally in the 3% – 5% range. 
However, some of the patients in this series had lower 
levels. Despite this fact, most of these patients exhibited 
decreased mental status, convulsion or syncope. Due to 
these findings such patients underwent HBOT treatment.14,15 
There were no statistically significant differences in COHb 
levels between smoker and non-smokers in this series.
 As expected, most patients in this series presented 
with mild rhabdomyolysis. This is in line with CO toxicity 
of skeletal muscle through the binding of heme-containing 
proteins.5 A rise in troponin was also observed, as elsewhere 
reported and agrees with cardiac muscle injury through CO 
mediated pathways involving mitochondrial dysfunction and 
free radical generation.5,15
 This case series includes other particular aspects 
such as inclusion of children and pregnant women. Both 
groups were assessed by paediatricians and obstetricians, 
respectively, prior to HBOT delivery. In all cases, treatment 
was well tolerated and none had the need to interrupt the 
session. Both fetus and mother showed no signs of distress 
before or after the treatment. Both groups should be 
treated like other patients with rapid initiation of NBOT and 
eventually HBOT.13
 Another strong reason for upfront institution of HBOT 
was to decrease the likelihood of late neurocognitive 
sequela, namely DNS. 
Delayed neuropsychiatric syndrome 
 DNS may present through a spectrum of neuropsy-
chiatric symptoms such as headache, difficulty 
concentrating, impairment of verbal fluency, lethargy, 
memory loss, dementia, psychosis, parkinsonism, chorea 
and peripheral neuropathy.5,8
 The occurrence of late neurological syndrome at 30 days 
occurred in 20% of the reassessed patients in this series. 
Notably, there was no statistical difference in median COHb 
when comparing the patients with symptoms of DNS and 
patients with no apparent sequalae. Moreover, there was 
no statistical difference in time to HBOT delivery. However, 
it should be noted that the difference was roughly nine 
hours in the group that developed DNS and six hours in 
the comparison group. Clinically, this three hour difference 
may have played its role considering that HBOT should 
ideally be initiated within the first six hours, as effectiveness 
decreases after that.7 Nevertheless, the majority of patients 
received HBOT in a timely manner. 
 Overall, these results are in line with what is previously 
published elsewhere. Severity of initial symptoms and 
COHb level do not allow for prediction of development of 
DNS according to recent research.5 Predictors of cognitive 
impairment in the first six weeks post-exposure have been 
described and include age ≥ 36 years, longer duration of 
CO exposure (≥ 24 hours) and loss of consciousness at the 
scene.5,18,19
 While most patients had low or moderate elevations 
of COHb, and some had a paucity of symptoms, HBOT 
treatment was still delivered as means to decrease the 
likelihood of DNS development. Moreover, like elsewhere 
stated, the purpose of HBOT is the prevention of long-
term and permanent neuropsychiatric sequalae, not 
improvement of short-term mortality rates, as these are 
around 3%, and to the present, studies have failed to show 
survival improvement with HBOT.7,18 Furthermore, NBOT 
treatment alone was found be no better than no oxygen 
in the prevention of DNS. With this in mind, HBOT should 
be considered for all cases of serious acute CO poisoning, 
which include loss of consciousness, electrocardiographic 
abnormalities, neurological symptoms, metabolic acidosis, 
regardless of COHb.13
 Median time to HBOT (< 6 hours) shows a timely 
intervention from the prevention team that runs the 
Hyperbaric Unit, especially considering the underlying 
conditions where this case series unfolded. DNS may 
develop several months after the initial exposure,8,20 
so a follow-up telephone contact was undertaken at 12 
months for clinical screening of symptoms related to 
DNS. No patients referred symptoms suggestive of DNS 
that warranted clinical evaluation. Notably, a limitation on 
defining DNS in this study is that it was defined based on 
clinical interview only, and not through specific cognitive 
tests. Furthermore, a basal neurocognitive background 
was not available or reported. Unfortunately, guidelines on 
follow-up of neuropsychiatric symptoms of CO poisoning 
are lacking. 20
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CONCLUSION
 Wildfires can cause clinically relevant CO poisoning, 
with typical signs and symptoms. This is a case of concern 
as Portugal experiences more and bigger wildfires each 
year. 
 We present a cohort of cases treated with HBOT that 
presented acutely to the emergency department in the time 
span of 72 hours, after CO poisoning from wildfires. This 
is an unheard number in Portugal at least. Availability of a 
hyperbaric chamber on location eased treatment with HBOT. 
While median COHb level was lower than other case series, 
the patients presented in an acute setting with persistent 
symptoms and with easy access to HBOT. Persistence of 
symptoms despite NBOT and an attempt to prevent DNS 
were the reasons for upfront HBOT, regardless of COHb 
level. In this study, the central tendency for patients who 
did not develop DNS was a time to delivery of HBOT below 
six hours. This may add to evidence on the importance of 
early HBOT on the prevention of DNS. Nevertheless, our 
results should be interpreted cautiously due to the low 
number of cases as well as lack of a control group treated 
solely with NBOT. To the best of our knowledge, this is the 
first Portuguese case series that reports the use of HBOT 
exclusively in CO poisoning due to wildfire exposure. With 
this publication, the authors intend to raise awareness 
regarding the importance and need for referral of this type 
of patients who in exceptional situations may go unnoticed 
but whose formal indication and benefits for this type of 
treatment are well documented, especially as the country 
has progressively experienced more and deadlier wildfires 
each year.
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